Optimizing Antibiotic Prescribing for Acute Respiratory Tract Infections in German Primary Care: Results of the Regional Intervention Study CHANGE-3 and the Nested cRCT.
antibacterial agents
antibiotic resistance
drug prescriptions
health communication
physician-patient relation
primary care
respiratory tract infection
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
04 May 2023
04 May 2023
Historique:
received:
04
04
2023
revised:
28
04
2023
accepted:
02
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Within primary care, acute respiratory tract infections (ARTIs) are the most common reason for prescribing antibiotics. The aim of the CHANGE-3 study was to investigate how antibiotic prescribing for non-complicated ARTIs can be reduced to a reasonable level. The trial was conducted as a prospective study consisting of a regional public awareness intervention in two regions of Germany and a nested cluster randomised controlled trial (cRCT) of a complex implementation strategy. The study involved 114 primary care practices and comprised an intervention period of six winter months for the nested cRCT and two times six winter months for the regional intervention. The primary outcome was the percentage of antibiotic prescribing for ARTIs between baseline and the two following winter seasons. The regression analysis confirmed a general trend toward the restrained use of antibiotics in German primary care. This trend was found in both groups of the cRCT without significant differences between groups. At the same time, antibiotic prescribing was higher in routine care (with the public campaign only) than in both groups of the cRCT. With regard to secondary outcomes, in the nested cRCT, the prescribing of quinolones was reduced, and the proportion of guideline-recommended antibiotics increased.
Identifiants
pubmed: 37237753
pii: antibiotics12050850
doi: 10.3390/antibiotics12050850
pmc: PMC10215067
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : German Federal Ministry of Health
ID : ZMVI1-2516FSB100
Références
Pharmacoepidemiol Drug Saf. 2009 Sep;18(9):763-9
pubmed: 19507170
Antibiotics (Basel). 2021 Sep 24;10(10):
pubmed: 34680732
JAMA. 2016 Feb 9;315(6):562-70
pubmed: 26864410
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003539
pubmed: 16235325
Cochrane Database Syst Rev. 2015 Nov 12;(11):CD010907
pubmed: 26560888
Lancet. 2016 Apr 23;387(10029):1743-52
pubmed: 26898856
BMC Fam Pract. 2020 Dec 19;21(1):274
pubmed: 33341114
Cochrane Database Syst Rev. 2017 Sep 07;9:CD004417
pubmed: 28881007
Fam Pract. 2004 Oct;21(5):500-6
pubmed: 15367471
J Antimicrob Chemother. 2007 Sep;60(3):638-44
pubmed: 17626023
Int J Pharm Pract. 2015 Oct;23(5):370-7
pubmed: 25711969
BMJ Qual Saf. 2011 Mar 21;20(9):764-772
pubmed: 21441602
Ann Intern Med. 2016 Mar 1;164(5):323-30
pubmed: 26833209
Implement Sci. 2018 Mar 20;13(1):47
pubmed: 29554972
Cochrane Database Syst Rev. 2017 Sep 07;9:CD012252
pubmed: 28881002
BMJ. 2021 Apr 28;373:n808
pubmed: 33910882